|
Eli Lilly and Company (LLY) DCF Valuation
US | Healthcare | Drug Manufacturers - General | NYSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Eli Lilly and Company (LLY) Bundle
Gain mastery over your Eli Lilly and Company (LLY) valuation analysis with our sophisticated DCF Calculator! Preloaded with real (LLY) data, this Excel template enables you to adjust forecasts and assumptions, allowing you to calculate Eli Lilly's intrinsic value with accuracy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24,539.8 | 28,318.4 | 28,541.4 | 34,124.1 | 45,042.7 | 52,670.9 | 61,591.0 | 72,021.8 | 84,219.0 | 98,481.9 |
| Revenue Growth, % | 0 | 15.4 | 0.78747 | 19.56 | 32 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 |
| EBITDA | 8,913.4 | 8,042.9 | 8,660.5 | 8,567.8 | 15,227.6 | 16,220.8 | 18,967.9 | 22,180.2 | 25,936.5 | 30,329.0 |
| EBITDA, % | 36.32 | 28.4 | 30.34 | 25.11 | 33.81 | 30.8 | 30.8 | 30.8 | 30.8 | 30.8 |
| Depreciation | 1,323.9 | 1,547.6 | 1,522.5 | 1,527.3 | 1,766.6 | 2,590.6 | 3,029.3 | 3,542.3 | 4,142.2 | 4,843.7 |
| Depreciation, % | 5.39 | 5.46 | 5.33 | 4.48 | 3.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 |
| EBIT | 7,589.5 | 6,495.3 | 7,138.0 | 7,040.5 | 13,461.0 | 13,630.2 | 15,938.6 | 18,637.8 | 21,794.2 | 25,485.2 |
| EBIT, % | 30.93 | 22.94 | 25.01 | 20.63 | 29.88 | 25.88 | 25.88 | 25.88 | 25.88 | 25.88 |
| Total Cash | 3,681.3 | 3,908.6 | 2,211.8 | 2,927.7 | 3,268.4 | 5,518.7 | 6,453.4 | 7,546.3 | 8,824.3 | 10,318.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 6,929.0 | 8,127.2 | 8,558.9 | 11,336.2 | .0 | 12,656.1 | 14,799.5 | 17,305.9 | 20,236.7 | 23,663.9 |
| Account Receivables, % | 28.24 | 28.7 | 29.99 | 33.22 | 0 | 24.03 | 24.03 | 24.03 | 24.03 | 24.03 |
| Inventories | 3,980.3 | 3,886.0 | 4,309.7 | 5,772.8 | .0 | 6,526.9 | 7,632.3 | 8,924.8 | 10,436.3 | 12,203.7 |
| Inventories, % | 16.22 | 13.72 | 15.1 | 16.92 | 0 | 12.39 | 12.39 | 12.39 | 12.39 | 12.39 |
| Accounts Payable | 1,606.7 | 1,670.6 | 1,930.6 | 2,598.8 | .0 | 2,826.0 | 3,304.6 | 3,864.2 | 4,518.6 | 5,283.9 |
| Accounts Payable, % | 6.55 | 5.9 | 6.76 | 7.62 | 0 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| Capital Expenditure | -2,029.1 | -1,873.2 | -2,484.0 | -7,392.1 | -8,403.6 | -6,732.0 | -7,872.1 | -9,205.2 | -10,764.2 | -12,587.2 |
| Capital Expenditure, % | -8.27 | -6.61 | -8.7 | -21.66 | -18.66 | -12.78 | -12.78 | -12.78 | -12.78 | -12.78 |
| Tax Rate, % | 16.49 | 16.49 | 16.49 | 16.49 | 16.49 | 16.49 | 16.49 | 16.49 | 16.49 | 16.49 |
| EBITAT | 6,501.8 | 5,889.8 | 6,549.0 | 5,628.9 | 11,241.9 | 11,764.5 | 13,756.9 | 16,086.7 | 18,811.0 | 21,996.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -3,506.0 | 4,524.2 | 4,992.1 | -3,808.1 | 19,115.1 | -8,733.9 | 6,144.0 | 7,184.5 | 8,401.2 | 9,824.0 |
| WACC, % | 5.88 | 5.88 | 5.89 | 5.87 | 5.87 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 17,353.8 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 10,217 | |||||||||
| Terminal Value | 544,134 | |||||||||
| Present Terminal Value | 408,963 | |||||||||
| Enterprise Value | 426,317 | |||||||||
| Net Debt | -3,268 | |||||||||
| Equity Value | 429,586 | |||||||||
| Diluted Shares Outstanding, MM | 904 | |||||||||
| Equity Value Per Share | 475.17 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Eli Lilly and Company’s (LLY) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing forecasts, validating strategies, and conserving time.
Key Features
- Pre-Loaded Data: Eli Lilly’s historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Customize WACC, tax rates, revenue growth, and EBITDA margins.
- Instant Results: View Eli Lilly’s intrinsic value recalculated in real time.
- Clear Visual Outputs: Dashboard charts illustrate valuation results and key metrics.
- Built for Accuracy: A professional tool designed for analysts, investors, and finance experts.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Eli Lilly data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Eli Lilly’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Eli Lilly and Company (LLY)?
- Accuracy: Utilizes verified Eli Lilly financial data for precise calculations.
- Flexibility: Allows users to experiment and adjust inputs as needed.
- Time-Saving: Eliminate the complexity of constructing a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and detail expected by financial professionals.
- User-Friendly: Intuitive interface suitable for users of all financial backgrounds.
Who Should Use This Product?
- Investors: Accurately assess Eli Lilly’s fair value before making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and analysis.
- Consultants: Easily modify the template for valuation reports tailored to clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by Fortune 500 firms.
- Educators: Implement it as a teaching resource to illustrate valuation techniques.
What the Template Contains
- Pre-Filled Data: Includes Eli Lilly's historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Eli Lilly's profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.